ID   ELOV2_RAT               Reviewed;         279 AA.
AC   D4A612;
DT   18-SEP-2013, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 1.
DT   24-JUL-2024, entry version 86.
DE   RecName: Full=Very long chain fatty acid elongase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE            EC=2.3.1.199 {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000269|PubMed:22216341, ECO:0000269|PubMed:23873268};
DE   AltName: Full=3-keto acyl-CoA synthase Elovl2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=ELOVL fatty acid elongase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE            Short=ELOVL FA elongase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=Elongation of very long chain fatty acids protein 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=Very long chain 3-ketoacyl-CoA synthase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
DE   AltName: Full=Very long chain 3-oxoacyl-CoA synthase 2 {ECO:0000255|HAMAP-Rule:MF_03202};
GN   Name=Elovl2 {ECO:0000255|HAMAP-Rule:MF_03202}; Synonyms=Ssc2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [2]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=22216341; DOI=10.1371/journal.pone.0029662;
RA   Gregory M.K., Gibson R.A., Cook-Johnson R.J., Cleland L.G., James M.J.;
RT   "Elongase reactions as control points in long-chain polyunsaturated fatty
RT   acid synthesis.";
RL   PLoS ONE 6:E29662-E29662(2011).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF CYS-217.
RX   PubMed=23873268; DOI=10.1194/jlr.m041368;
RA   Gregory M.K., Cleland L.G., James M.J.;
RT   "Molecular basis for differential elongation of omega-3 docosapentaenoic
RT   acid by the rat Elovl5 and Elovl2.";
RL   J. Lipid Res. 54:2851-2857(2013).
CC   -!- FUNCTION: Catalyzes the first and rate-limiting reaction of the four
CC       reactions that constitute the long-chain fatty acids elongation cycle.
CC       This endoplasmic reticulum-bound enzymatic process allows the addition
CC       of 2 carbons to the chain of long- and very long-chain fatty acids
CC       (VLCFAs) per cycle. Condensing enzyme that catalyzes the synthesis of
CC       polyunsaturated very long chain fatty acid (C20- and C22-PUFA), acting
CC       specifically toward polyunsaturated acyl-CoA with the higher activity
CC       toward C20:4(n-6) acyl-CoA. May participate in the production of
CC       polyunsaturated VLCFAs of different chain lengths that are involved in
CC       multiple biological processes as precursors of membrane lipids and
CC       lipid mediators. {ECO:0000255|HAMAP-Rule:MF_03202,
CC       ECO:0000269|PubMed:22216341, ECO:0000269|PubMed:23873268}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a very-long-chain acyl-CoA + H(+) + malonyl-CoA = a very-long-
CC         chain 3-oxoacyl-CoA + CO2 + CoA; Xref=Rhea:RHEA:32727,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16526, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57384, ChEBI:CHEBI:90725, ChEBI:CHEBI:90736;
CC         EC=2.3.1.199; Evidence={ECO:0000255|HAMAP-Rule:MF_03202,
CC         ECO:0000269|PubMed:22216341, ECO:0000269|PubMed:23873268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:32728;
CC         Evidence={ECO:0000305|PubMed:22216341};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA + H(+) + malonyl-CoA
CC         = (9Z,12Z,15Z,18Z,21Z)-3-oxotetracosapentaenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36491, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57384, ChEBI:CHEBI:73870,
CC         ChEBI:CHEBI:73871; Evidence={ECO:0000269|PubMed:22216341,
CC         ECO:0000269|PubMed:23873268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36492;
CC         Evidence={ECO:0000305|PubMed:22216341};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA + H(+) + malonyl-CoA
CC         = (7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36483, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57384, ChEBI:CHEBI:73862,
CC         ChEBI:CHEBI:73863; Evidence={ECO:0000269|PubMed:22216341,
CC         ECO:0000269|PubMed:23873268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36484;
CC         Evidence={ECO:0000305|PubMed:22216341};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + H(+) + malonyl-CoA =
CC         (7Z,10Z,13Z,16Z)-3-oxodocosatetraenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36475, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57368, ChEBI:CHEBI:57384,
CC         ChEBI:CHEBI:73852; Evidence={ECO:0000269|PubMed:22216341};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36476;
CC         Evidence={ECO:0000305|PubMed:22216341};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(7Z,10Z,13Z,16Z)-docosatetraenoyl-CoA + H(+) + malonyl-CoA =
CC         (9Z,12Z,15Z,18Z)-3-oxotetracosatetraenoyl-CoA + CO2 + CoA;
CC         Xref=Rhea:RHEA:36479, ChEBI:CHEBI:15378, ChEBI:CHEBI:16526,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57384, ChEBI:CHEBI:73856,
CC         ChEBI:CHEBI:73857; Evidence={ECO:0000269|PubMed:22216341};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36480;
CC         Evidence={ECO:0000305|PubMed:22216341};
CC   -!- PATHWAY: Lipid metabolism; polyunsaturated fatty acid biosynthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_03202, ECO:0000269|PubMed:22216341,
CC       ECO:0000269|PubMed:23873268}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000255|HAMAP-Rule:MF_03202}; Multi-pass membrane protein
CC       {ECO:0000255|HAMAP-Rule:MF_03202}.
CC   -!- DOMAIN: The C-terminal di-lysine motif may confer endoplasmic reticulum
CC       localization. {ECO:0000255|HAMAP-Rule:MF_03202}.
CC   -!- SIMILARITY: Belongs to the ELO family. ELOVL2 subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_03202}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AABR06090841; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR06090842; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR06090843; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR06090844; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AABR06090845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH473977; EDL98219.1; -; Genomic_DNA.
DR   EMBL; CH473977; EDL98220.1; -; Genomic_DNA.
DR   RefSeq; NP_001102588.1; NM_001109118.1.
DR   RefSeq; XP_006253841.1; XM_006253779.3.
DR   AlphaFoldDB; D4A612; -.
DR   SMR; D4A612; -.
DR   BioGRID; 270038; 1.
DR   STRING; 10116.ENSRNOP00000019756; -.
DR   SwissLipids; SLP:000000273; -.
DR   iPTMnet; D4A612; -.
DR   PhosphoSitePlus; D4A612; -.
DR   PaxDb; 10116-ENSRNOP00000019756; -.
DR   Ensembl; ENSRNOT00000019756.7; ENSRNOP00000019756.5; ENSRNOG00000014702.7.
DR   Ensembl; ENSRNOT00055012430; ENSRNOP00055009866; ENSRNOG00055007448.
DR   Ensembl; ENSRNOT00060015021; ENSRNOP00060011653; ENSRNOG00060008946.
DR   Ensembl; ENSRNOT00065012996; ENSRNOP00065009577; ENSRNOG00065008205.
DR   GeneID; 498728; -.
DR   KEGG; rno:498728; -.
DR   UCSC; RGD:1308605; rat.
DR   AGR; RGD:1308605; -.
DR   CTD; 54898; -.
DR   RGD; 1308605; Elovl2.
DR   eggNOG; KOG3071; Eukaryota.
DR   GeneTree; ENSGT01050000244838; -.
DR   HOGENOM; CLU_048483_0_1_1; -.
DR   InParanoid; D4A612; -.
DR   OrthoDB; 168669at2759; -.
DR   PhylomeDB; D4A612; -.
DR   TreeFam; TF323454; -.
DR   Reactome; R-RNO-2046105; Linoleic acid (LA) metabolism.
DR   Reactome; R-RNO-2046106; alpha-linolenic acid (ALA) metabolism.
DR   Reactome; R-RNO-75876; Synthesis of very long-chain fatty acyl-CoAs.
DR   UniPathway; UPA00658; -.
DR   PRO; PR:D4A612; -.
DR   Proteomes; UP000002494; Chromosome 17.
DR   Proteomes; UP000234681; Chromosome 17.
DR   Bgee; ENSRNOG00000014702; Expressed in testis and 12 other cell types or tissues.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0016747; F:acyltransferase activity, transferring groups other than amino-acyl groups; ISO:RGD.
DR   GO; GO:0009922; F:fatty acid elongase activity; ISO:RGD.
DR   GO; GO:0034625; P:fatty acid elongation, monounsaturated fatty acid; IBA:GO_Central.
DR   GO; GO:0034626; P:fatty acid elongation, polyunsaturated fatty acid; ISO:RGD.
DR   GO; GO:0019367; P:fatty acid elongation, saturated fatty acid; IBA:GO_Central.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IBA:GO_Central.
DR   GO; GO:0006636; P:unsaturated fatty acid biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0042761; P:very long-chain fatty acid biosynthetic process; ISO:RGD.
DR   GO; GO:0000038; P:very long-chain fatty acid metabolic process; ISO:RGD.
DR   HAMAP; MF_03202; VLCF_elongase_2; 1.
DR   InterPro; IPR030457; ELO_CS.
DR   InterPro; IPR002076; ELO_fam.
DR   InterPro; IPR033680; ELOVL2.
DR   PANTHER; PTHR11157:SF16; ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 2; 1.
DR   PANTHER; PTHR11157; FATTY ACID ACYL TRANSFERASE-RELATED; 1.
DR   Pfam; PF01151; ELO; 1.
DR   PROSITE; PS01188; ELO; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Fatty acid biosynthesis; Fatty acid metabolism;
KW   Lipid biosynthesis; Lipid metabolism; Membrane; Reference proteome;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..279
FT                   /note="Very long chain fatty acid elongase 2"
FT                   /id="PRO_0000423425"
FT   TRANSMEM        12..32
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        50..70
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        98..118
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        136..156
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        158..178
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        188..208
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   TRANSMEM        213..233
FT                   /note="Helical"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   MOTIF           276..279
FT                   /note="Di-lysine motif"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_03202"
FT   MUTAGEN         217
FT                   /note="C->A: Decreased elongase activity toward
FT                   (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA."
FT                   /evidence="ECO:0000269|PubMed:23873268"
FT   MUTAGEN         217
FT                   /note="C->F: Decreased elongase activity toward
FT                   (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA."
FT                   /evidence="ECO:0000269|PubMed:23873268"
FT   MUTAGEN         217
FT                   /note="C->W: Loss of elongase activity toward
FT                   (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA."
FT                   /evidence="ECO:0000269|PubMed:23873268"
SQ   SEQUENCE   279 AA;  32417 MW;  6D3103A7470E8A14 CRC64;
     MFGPRDSRVR GWFLLDSYLP TFTLTIVYLL SIWLGNKYMK NRPALSLRGI LTLYNLGITL
     LSAYMLVELV LSSWEGGYNL QCQNLDSAGE GDIRVAKVLW WYYFSKLVEF LDTIFFVLRK
     KTSQITFLHV YHHASMFNIW WCVLNWIPCG QSFFGPTLNS FIHILMYSYY GLSVFPSMHR
     YLWWKKYLTQ AQLVQFVLTI THTLSAVVKP CGFPFGCLIF QSSYMMTLVI LFLNFYIQTY
     RKKPMKKEMP EGAAGKEVKN GFPKAHSIAA NGVTDKKVQ
//
